Usefulness of linezolid in the treatment of hospital-acquired pneumonia caused by MRSA: A prospective observational study

Journal of Infection and Chemotherapy

Volumn 18, Issue 2, 2012, Pages 160-168

  Watanabe, Akira ^a   Goto, Hajime ^b   Soma, Kazui ^c   Kikuchi, Toshiaki ^d   Gomi, Kazunori ^d   Miki, Hiroshi ^e   Maemondo, Makoto ^f   Ikeda, Hideki ^g   Kuroki, Jun ^h   Wada, Hiroo ^b   Yokoyama, Takuma ^b   Izumi, Shinyu ⁱ   Mitsutake, Kotaro ^j   Ueda, Yasuharu ^k,l  

^a TOHOKU UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e SENDAI CITY MEDICAL CENTER   (Japan)

^f Miyagi Cancer Center   (Japan)

^g Sanyudo Hospital   (Japan)

^h Yuri Kumiai General Hospital   (Japan)

ⁱ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^j SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^k NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^l Seichikai Memorial Hospital   (Japan)

more..

Author keywords

Hospital acquired pneumonia; Linezolid; Methicillin resistant Staphylococcus aureus (MRSA); Usefulness

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; JAPANESE; LEUKOPENIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84863306963     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0309-z     Document Type: Article

References (25)

1. González C, Rubio M, Romeo-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillinsusceptible organisms. Clin Infect Dis. 1999;29:1171-7.
2. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-74.
3. Nosocomial Infection Study Group. Antibiotic sensitivity surveillance report 2000. Tokyo: Jiho, Inc.; 2000.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-6.
5. Shimada K. Recent findings based on the results of the postmarketing surveillance of vancomycin hydrochloride for intravenous infusion. Jpn J Antibiot. 2003;56:259-71 (in Japanese).
6. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilatorassociated pneumonia. Crit Care Med. 2005;33:1529-33.
7. Clemett D, Markham A. Linezolid. Drugs. 2000;59:815-27.
8. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs. 2001;61:525-51.
9. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. The Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, doubleblind, multicenter study. Clin Infect Dis. 2001;32:402-12.
10. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481-90.
11. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, The Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980-92.
12. Kaplan SL, Afghani B, Lopez P, Wu E, Fleishaker D, Edge- Padbury B, et al. Linezolid for the treatment of methicillinresistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2003;22(Suppl 9):178-85.
13. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60:1361-9.
14. The Committee for the JRS Guidelines in the Management of Respiratory Infections. The Japanese Respiratory Society guidelines for management of hospital-acquired pneumonia. Tokyo: The Japanese Respiratory Society; 2002 (Japanese).
15. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23.
16. Aikawa N, Kohno S, Kaku M, Watanabe A, Yamaguchi K, Tanigawara Y. An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA)-a clinical pharmacology study. J Chemother. 2008;56:299-312 (Japanese).
17. Kohno S, Watanabe A, Matsushima T, HAP Study Group. Nationwide multicenter survey on the pathophysiology of hospital- acquired pneumonia and the use of first-line antibiotics in Japan: evaluation of clinical position of meropenem in the initial therapy of hospital-acquired pneumonia. J Chemother. 2006;54:453-64 (Japanese).
18. Watanabe A, Yanagihara K, Kohno S, Matsushima T, HAP Study Group. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Internal Med. 2008;47:245-54.
19. Kato T, Sato F, Horino T, Nakazawa Y, Sakamoto M, Yoshida M, et al. Clinical features of 15 cases treated with linezolid. J Chemother. 2008;56:202-5 (Japanese).
20. Kato M, Hisada T, Ishizuka T, Aoki H, Yanagitani N, Kaira K, et al. An elderly case of severe MRSA pneumonia successfully treated with linezolid. Kitakanto Med J. 2008;58:81-6 (Japanese).
21. Luna CM, Boyeras Navarro ID. Management of methicillinresistant Staphylococcus aureus pneumonia. Curr Opin Infect Dis. 2010;23:178-84.
22. Albrecht J, Meves A, Bigby M. Case reports and case series from Lancet had significant impact on medical literature. J Clin Epidemiol. 2005;58:1227-32.
23. Kooistra B, Dijkman B, Einhorn TA, Bhandari M. How to design a good case series. J Bone Joint Surg Am. 2009;91(Suppl 3): 21-6.
24. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):378-85.
25. Niederman MS. Treatment options for nosocomial pneumonia due to MRSA. J Infect. 2009;59(Suppl 1):25-31.